Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 3/2017

06.10.2016 | Original Article

The miR-125a-3p Inhibits TIM-3 Expression in AML Cell Line HL-60 In Vitro

verfasst von: Fatemeh Emamdoost, Hossein Khanahmad, Mazdak Ganjalikhani-hakemi, Abbas Doosti

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Acute Myeloid Leukemia is a cancer of leukemic stem cells (LSCs) with a rapid progression. It is characterized by overproduction of immature myeloid cells in bone marrow which crowds out normal hematopoietic stem cells (HSC). TIM-3, an immune regulatory molecule, is an LSC specific surface marker in AML with high expression on these cells compared to HSCs. Studies have indicated that micro RNAs (miRNAs) may play an important role in either cancer progression or suppression. Based on bioinformatics assessments, we have predicted that miR-125a-3p could be a miRNA with high suppressive activity on TIM-3 expression. The purpose of this study was to investigate the inhibitory effect of miR-125a-3p on TIM-3 gene expression in an AML cell line, HL-60, in vitro. HL-60 cells were cultured in RPMI 1640 supplied with 10 % FBS. TIM-3 expression was induced on the cells using phorbol miristate acetate. The cells were transfected with miR-125-3p for 24 h and the gene and protein expression of TIM-3 were measured using q-RT-PCR and flow-cytometery methods, respectively. The results of this study showed that miR-125a-3p has a strong silencing effect on TIM-3 gene and protein expression on HL-60 cell line. Based to our results, miR125a-3p can strongly silence TIM-3 expression in AML cell line. Thus, our results have confirmed the bioinformatics prediction of suppressive effect of miR-125a-3p on TIM-3with Mirwalk and Target Scan softwares.
Literatur
1.
Zurück zum Zitat Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC et al (2006) Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: pediatric Oncology Group Study 9421. Blood 107(4):1315–1324CrossRefPubMedPubMedCentral Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC et al (2006) Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: pediatric Oncology Group Study 9421. Blood 107(4):1315–1324CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Sperr W, Wimazal F, Kundi M, Fonatsch C, Thalhammer-Scherrer R, Schernthaner G et al (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 80(5):272–277CrossRefPubMed Sperr W, Wimazal F, Kundi M, Fonatsch C, Thalhammer-Scherrer R, Schernthaner G et al (2001) Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 80(5):272–277CrossRefPubMed
3.
Zurück zum Zitat Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous. Blood 75(10):1932–1940PubMed Creutzig U, Ritter J, Schellong G (1990) Identification of two risk groups in childhood acute myelogenous. Blood 75(10):1932–1940PubMed
4.
Zurück zum Zitat Sayehmiri K, Eshraghian MR, Mohammad K, Alimoghaddam K, Foroushani AR, Zeraati H et al (2008) Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: cox proportional hazard versus accelerated failure time models. J Exp Clin Cancer Res 27(1):1–9CrossRef Sayehmiri K, Eshraghian MR, Mohammad K, Alimoghaddam K, Foroushani AR, Zeraati H et al (2008) Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: cox proportional hazard versus accelerated failure time models. J Exp Clin Cancer Res 27(1):1–9CrossRef
5.
Zurück zum Zitat Arnaout M, Radomski K, Srivastava D, Tong X, Belt J, Raimondi S et al (2000) Treatment of childhood acute myelogenous leukemia with an intensive regimen(AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects. Leukemia 14(10):1736–1742CrossRefPubMed Arnaout M, Radomski K, Srivastava D, Tong X, Belt J, Raimondi S et al (2000) Treatment of childhood acute myelogenous leukemia with an intensive regimen(AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects. Leukemia 14(10):1736–1742CrossRefPubMed
6.
Zurück zum Zitat Gleason MK, Lenvik TR, McCullar V, Felices M, O’Brien MS, Cooley SA et al (2012) Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 119(13):3064–3072CrossRefPubMedPubMedCentral Gleason MK, Lenvik TR, McCullar V, Felices M, O’Brien MS, Cooley SA et al (2012) Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 119(13):3064–3072CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL et al (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci 108(12):5009–5014CrossRefPubMedPubMedCentral Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL et al (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci 108(12):5009–5014CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6(12):1245–1252CrossRefPubMed Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6(12):1245–1252CrossRefPubMed
9.
Zurück zum Zitat Kikushige Y, Shima T, S-i Takayanagi, Urata S, Miyamoto T, Iwasaki H et al (2010) TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7(6):708–717CrossRefPubMed Kikushige Y, Shima T, S-i Takayanagi, Urata S, Miyamoto T, Iwasaki H et al (2010) TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 7(6):708–717CrossRefPubMed
10.
Zurück zum Zitat Zhong X, Coukos G, Zhang L (2012) miRNAs in human cancer. Next-generation MicroRNA expression profiling technology. Springer, Berlin, pp 295–306CrossRef Zhong X, Coukos G, Zhang L (2012) miRNAs in human cancer. Next-generation MicroRNA expression profiling technology. Springer, Berlin, pp 295–306CrossRef
11.
Zurück zum Zitat Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefPubMed Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674CrossRefPubMed
12.
Zurück zum Zitat Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer 43(10):1529–1544CrossRefPubMed Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer 43(10):1529–1544CrossRefPubMed
13.
Zurück zum Zitat Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ (2012) Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 81(2):103–122CrossRefPubMed Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ (2012) Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 81(2):103–122CrossRefPubMed
14.
Zurück zum Zitat Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42(8):1273–1281CrossRefPubMed Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42(8):1273–1281CrossRefPubMed
15.
Zurück zum Zitat Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M et al (2009) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113(16):3821–3830CrossRefPubMed Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M et al (2009) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113(16):3821–3830CrossRefPubMed
16.
17.
Zurück zum Zitat Kikushige Y, Shima T, Yuda J, Miyamoto T, Akashi K, editors. Leukemogenic function of TIM-3, a leukemia stem cell marker, in acute myelogenous leukemia and myelodysplastic syndromes. ASH Annual Meeting Abstracts; 2012 Kikushige Y, Shima T, Yuda J, Miyamoto T, Akashi K, editors. Leukemogenic function of TIM-3, a leukemia stem cell marker, in acute myelogenous leukemia and myelodysplastic syndromes. ASH Annual Meeting Abstracts; 2012
18.
Zurück zum Zitat Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X et al (2010) Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 10(1):318CrossRefPubMedPubMedCentral Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X et al (2010) Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 10(1):318CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hashiguchi Y, Nishida N, Mimori K, Sudo T, Tanaka F, Shibata K et al (2012) Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol 40(5):1477–1482PubMed Hashiguchi Y, Nishida N, Mimori K, Sudo T, Tanaka F, Shibata K et al (2012) Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol 40(5):1477–1482PubMed
20.
Zurück zum Zitat Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N et al (2014) MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience 1(4):250CrossRefPubMedPubMedCentral Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N et al (2014) MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience 1(4):250CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Tang H, Li RP, Liang P, Zhou YL, Wang GW miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett Tang H, Li RP, Liang P, Zhou YL, Wang GW miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett
22.
Zurück zum Zitat Ufkin ML, Peterson S, Yang X, Driscoll H, Duarte C, Sathyanarayana P (2014) miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res 38(3):402–410CrossRefPubMedPubMedCentral Ufkin ML, Peterson S, Yang X, Driscoll H, Duarte C, Sathyanarayana P (2014) miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res 38(3):402–410CrossRefPubMedPubMedCentral
Metadaten
Titel
The miR-125a-3p Inhibits TIM-3 Expression in AML Cell Line HL-60 In Vitro
verfasst von
Fatemeh Emamdoost
Hossein Khanahmad
Mazdak Ganjalikhani-hakemi
Abbas Doosti
Publikationsdatum
06.10.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 3/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0733-4

Weitere Artikel der Ausgabe 3/2017

Indian Journal of Hematology and Blood Transfusion 3/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.